Breaking News Instant updates and real-time market news.

SPLK

Splunk

$57.38

-0.04 (-0.07%)

, GWRE

Guidewire

$57.55

-0.82 (-1.40%)

17:23
11/29/16
11/29
17:23
11/29/16
17:23

On The Fly: After Hours Movers

UP AFTER EARNINGS: Splunk (SPLK), up 4.5%... Guidewire (GWRE), up 2.5%. ALSO HIGHER: Ballard Power (BLDP), up 3.7% after it signed a supply agreement with Solaris. DOWN AFTER EARNINGS: Autodesk (ADSK), down 2.9%... Nutanix (NTNX), down 1.7%. ALSO LOWER: Arrowhead (ARWR), down 59.9% after it announced it will halt development of all EX1 programs and cut 30% of its workforce... Costamare (CMRE), down 8% after filing to sell 11M shares of common stock... Evolent Health (EVH), down 7.2% after filing to sell $110M in convertible senior notes due 2021.

SPLK

Splunk

$57.38

-0.04 (-0.07%)

GWRE

Guidewire

$57.55

-0.82 (-1.40%)

BLDP

Ballard Power

$1.91

-0.04 (-2.05%)

ADSK

Autodesk

$75.26

0.08 (0.11%)

NTNX

Nutanix

$34.09

0.75 (2.25%)

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

CMRE

Costamare

$6.65

-0.47 (-6.60%)

EVH

Evolent Health

$18.85

-1.45 (-7.14%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 08

    Dec

  • 13

    Dec

  • 11

    Jan

  • 30

    Nov

SPLK Splunk
$57.38

-0.04 (-0.07%)

11/28/16
WBLR
11/28/16
NO CHANGE
WBLR
Outperform
Splunk risk/reward favorable into earnings, says William Blair
William Blair analyst Bhavan Suri says almost every Splunk partner his firm spoke with indicated that business was at least in line with expectations during the quarter. His work suggests $3M-$6M outperformance on total revenue for Splunk's Q3, which could translate to modest upside on operating income and earnings. The analyst views the stock's risk/reward as favorable into tomorrow's results. Suri keeps an Outperform rating on Splunk.
11/28/16
JMPS
11/28/16
NO CHANGE
JMPS
Splunk made major deal with State Department, says JMP Securities
JMP Securities analyst Greg McDowell reports that Splunk made "a multiyear federal deal with the State Department" worth a total of $25M. The analyst says that the contract could be "the largest federal deal in Splunk's history." He keeps a $70 price target and an Outperform rating on the shares.
10/04/16
GUGG
10/04/16
DOWNGRADE
GUGG
Neutral
Splunk downgraded to Neutral from Buy at Guggenheim
10/14/16
PIPR
10/14/16
INITIATION
Target $70
PIPR
Overweight
Splunk assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Alex Zukin assumed coverage of Splunk with an Overweight rating and $70 price target. The analyst views the company as a "category-defining market leader that essentially throws a paddle to companies swimming in a sea of data." He sees few direct competitors and a $45B total addressable market.
GWRE Guidewire
$57.55

-0.82 (-1.40%)

10/04/16
GSCO
10/04/16
INITIATION
Target $57
GSCO
Neutral
Guidewire initiated with a Neutral at Goldman
Goldman analyst Jesse Hulsing initiated Guidewire with a Neutral and a $57 price target saying shares are fairly valued.
09/16/16
09/16/16
DOWNGRADE
Target $60

Underperform
Guidewire downgraded to Underperform on valuation at BofA/Merrill
As previously reported, BofA downgraded Guidewire to Underperform from Neutral and lowered its price target to $60 from $64. Analyst Brad Sills said Guidewire are trading at a premium to peers and shares are fully valued.
09/16/16
BOFA
09/16/16
DOWNGRADE
BOFA
Underperform
Guidewire downgraded to Underperform from Neutral at BofA/Merrill
09/08/16
UBSW
09/08/16
NO CHANGE
Target $70
UBSW
Buy
Guidewire weakness a buying opportunity, says UBS
UBS analyst Brent Thill noted Guidewire investors may be concerned about its 2017 guidance, but he believes it is conservative from a historical perspective. The analyst feels any weakness in Guidewire shares would be a buying opportunity, citing its zero churn rate, stable P&C insurance end market, increasing customer referencing, and the long commitments that P&C insurers make to the company. Thill reiterated his Buy rating and $70 price target on Guidewire shares.
BLDP Ballard Power
$1.91

-0.04 (-2.05%)

02/03/16
ROTH
02/03/16
NO CHANGE
Target $2
ROTH
Buy
Ballard Power coverage assumed with a Buy at Roth Capital
Target $2.
02/19/16
FBRC
02/19/16
INITIATION
Target $1.5
FBRC
Market Perform
Ballard Power initiated with a Market Perform at FBR Capital
FBR Capital analyst Carter Driscoll started Ballard Power Systems with a Market Perform rating and $1.50 price target.
07/28/16
FBRC
07/28/16
UPGRADE
Target $3
FBRC
Outperform
Ballard Power upgraded to Outperform from Market Perform at FBR Capital
FBR Capital analyst Carter Driscoll upgraded Ballard Power Systems to Outperform saying the company's Chinese partnerships should change its profile. The analyst has a $3 price target for the shares.
07/28/16
07/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Buy from Long-Term Buy at Hilliard Lyons with analyst Stephen Turner saying he views Apple's guidance as "solid." The analyst raised his price target for the shares to $131 from $121 following the company's third quarter results. 2. Ballard Power (BLDP) upgraded to Outperform from Market Perform at FBR Capital with analyst Carter Driscoll saying the company's Chinese partnerships should change its profile. 3. U.S. Steel (X) upgraded to Buy from Hold at Argus with analyst David Coleman saying he expects the company to benefit from margin expansion, new tariffs, a stable to falling dollar and a sooner than expected return to profitability after its second quarter profits beat expectations. 4. TripAdvisor (TRIP) upgraded to Market Perform from Underperform at Raymond James with analyst Justin Patterson citing relative valuation, easing comps limit the likelihood of further 10%+ cuts to EBITDA, and reduced negative catalysts. 5. Barrick Gold (ABX) upgraded to Buy from Hold at Canaccord with the firm saying it sees operational improvements and the balance sheet improving in addition to relative valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ADSK Autodesk
$75.26

0.08 (0.11%)

11/21/16
BARD
11/21/16
NO CHANGE
Target $85
BARD
Outperform
Autodesk price target raised to $85 from $75 at Baird
Baird analyst Steven Ashley raised his price target on Autodesk to $85 from $75 following mixed channel check results that were consistent with guidance. The analyst remains bullish on the shares as he believes there will be a steady stream of positive forward-looking metrics beginning next quarter, including subscriber growth, ARR, and deferred revenue. Ashley reiterated his Outperform rating on Autodesk shares.
11/22/16
WEDB
11/22/16
NO CHANGE
WEDB
Autodesk checks mixed, says Wedbush
After conducting checks with resellers, Wedbush analyst Steve Koenig thinks that Autodesk's net subscriber additions were "strong" in Q3, while its revenue outlook for 2H16 "looks middling." The analyst adds that the company's Q3 revenue appears to have been "mostly in-line with muted...expectations," while there were "isolated reports" of November beginning weaker than expected. He raised his price target on the shares to $70 from $60 and reiterates a Neutral rating.
08/30/16
08/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autodesk (ADSK) downgraded to Sell from Neutral at Rosenblatt, as analyst Kirk Adams believes the shares are "priced for perfection" through fiscal year 2020. 2. Pacific Crest analyst Rob Owens downgraded Imperva (IMPV) to Sector Weight from Overweight, saying the company's fundamentals continue to be challenged. The analyst sees a "limited number" of strategic suitors for Imperva and thinks the current share price could prevent "meaningful upside" should a buyer step in. Owens coupled the downgrade with upgrades this morning of Barracuda (CUDA) and Fortinet (FTNT) to Overweight. 3. ManTech (MANT) downgraded to Underperform from Market Perform at Wells Fargo, with analyst Ed Caso citing valuation. Caso believes the shares are "ahead of themselves" and he keeps a $33-$34 price target range for the name. 4. Signet Jewelers (SIG) downgraded to Neutral from Overweight at JPMorgan by analyst Anne Samuel, citing fundamental headwinds after the company lowered its 2017 outlook. 5. Seaport Global analysts led by Mike Kelly downgraded Rice Energy (RICE) and Marathon Oil (MRO), each to Neutral from Buy, citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/16
EVER
09/14/16
INITIATION
Target $80
EVER
Buy
Autodesk initiated with a Buy at Evercore ISI
Target $80.
NTNX Nutanix
$34.09

0.75 (2.25%)

10/25/16
MSCO
10/25/16
INITIATION
Target $27
MSCO
Equal Weight
Nutanix initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Katy Huberty initiated Nutanix with an Equal Weight and a $27 price target due to valuation.
10/25/16
KEYB
10/25/16
INITIATION
KEYB
Overweight
Nutanix initiated with an Overweight at KeyBanc
Target $37.
10/25/16
WBLR
10/25/16
INITIATION
WBLR
Outperform
Nutanix initiated with an Outperform at William Blair
William Blair analyst Jason Ader started Nutanix with an Outperform rating saying the risk/reward is attractive given the company's growth profile.
10/25/16
10/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hershey (HSY) initiated with a Neutral at Susquehanna. 2. Nutanix (NTNX) initiated with an Outperform at Credit Suisse, an Overweight at Piper Jaffray, a Neutral at JPMorgan, a Hold at Stifel, a Neutral at Goldman, a Market Perform at Raymond James, an Outperform at Baird, an Outperform at RBC Capital, an Outperform at Oppenheimer, a Buy at Needham, an Equal Weight at Morgan Stanley, an Overweight at KeyBanc, and an Outperform at William Blair. 3. LabCorp (LH) initiated with a Buy at Gabelli. 4. AAR Corp. initiated with a Buy at Gabelli. 5. Hain Celestial (HAIN) initiated with a Positive at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ARWR Arrowhead
$4.39

-0.07 (-1.57%)

09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
CMRE Costamare
$6.65

-0.47 (-6.60%)

10/05/16
JPMS
10/05/16
UPGRADE
Target $13
JPMS
Overweight
Costamare upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Noah Parquette upgraded Costamare to Overweight saying that while the dividend cut is unfortunate, it solidifies the company's liquidity position. Costamare will have a "relatively stable" cash flow profile in 2016 and 2017 given its high charter coverage, Parquette tells investors in a research note. He raised his price target for the shares to $13 from $12.
10/04/16
STFL
10/04/16
DOWNGRADE
STFL
Sell
Costamare downgraded to Sell from Hold at Stifel
06/30/16
MSCO
06/30/16
DOWNGRADE
Target $7.5
MSCO
Equal Weight
Costamare downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Fotis Giannakoulis downgraded Costamare to Equal Weight and lowered its price target $7.50 from $12. The analyst said macro uncertainty and prolonged weakness in the container shipping industry will result in an earnings decline and lower dividend.
08/01/16
JPMS
08/01/16
UPGRADE
Target $12
JPMS
Neutral
Costamare upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Noah Parquette upgraded Costamare to Neutral saying the company's cash flow profile in 2016 and 2017 will be stable given the company's high charter coverage. The analyst remains concerned of a dividend cut over the next 6-12 months amid deteriorating container spot rates, however. He raised his price target for Costamare shares to $12 from $11.
EVH Evolent Health
$18.85

-1.45 (-7.14%)

11/16/16
WBLR
11/16/16
NO CHANGE
WBLR
Outperform
William Blair calls Evolent top small-cap alpha generation idea
William Blair analyst Ryan Daniels listed his top 10 reasons for why the recent pullback in shares of Evolent Health creates a good entry point. Much of the post-quarter weakness relates to the recent election results, as investors weigh the uncertainty created by a Republican-controlled White House and Congress along with the party's objective to immediately repeal and replace the Affordable Care Act, Daniels tells investors in a research note. The analyst believes the "movement to value-based care in the United States will continue apace" and has "strong" bipartisan support. He also believes Evolent Health's momentum "is quite strong." It is unlikely that the new administration will disrupt the insurance markets so much that tens of millions of Americans suddenly lose coverage in 2019, Daniels tells investors in a research note. He calls Evolent his top small-cap alpha generation idea over the next 12 months and reiterates an Outperform rating on the name.
11/21/16
LEER
11/21/16
NO CHANGE
Target $24
LEER
Outperform
Leerink continues positive on Evolent Health heading into 2017
Leerink analyst David Larsen continues to be positive on Evolent Health heading into 2017, and says that management has consistently delivered on promises, including five new partner relationships in 2016, steady organic growth in lives-on-platform from existing customers, a high degree of recurring revenue and steady improvement in EBITDA. The analyst reiterated an Outperform rating on the stock but lowered his price target on the shares to $24 from $28.
11/22/16
ADAM
11/22/16
NO CHANGE
Target $31
ADAM
Buy
Evolent Health remains a top pick at Canaccord
Canaccord analyst Richard Close had investor meetings with Evolent Health and came away with confidence that 2017 estimates are conservative. The analyst continues to call Evolent a to pick, citing its significant pipeline of new business, new client wins and penetration of existing clients, and the opportunity to triple its business within its existing client base. Close reiterated his Buy rating and $31 price target on Evolent Health shares.
11/15/16
COWN
11/15/16
NO CHANGE
Target $35
COWN
Outperform
Evolent Health weakness offers attractive entry point, says Cowen
Cowen analyst Charles Rhyee believes the 10% pullback in Evolent Health shares since the election reflects concerns that repealing and replacing the ACA could mean there will be no more Medicaid expansion. However, he thinks the provision eliminating Medicaid expansion and the associated Federal Medical Assistance Percentages increase may not be included in the Republican ACA-repeal provisions. Also, Rhyee thinks a transition to value-based care will continue even if the ACA is repealed and replaced. He recommends buying amid the post-election weakness and reiterate his $35 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NOV

National Oilwell

$35.37

0.19 (0.54%)

10:52
09/20/17
09/20
10:52
09/20/17
10:52
Options
National Oilwell calls outpace puts 18:1 as shares jump »

National Oilwell calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

ZLAB

Zai Lab

10:51
09/20/17
09/20
10:51
09/20/17
10:51
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STX

Seagate

$32.18

-1.34 (-4.00%)

10:50
09/20/17
09/20
10:50
09/20/17
10:50
Options
Short-term calls on Seagate see interest for a second time this week »

Short-term calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$237.42

-2.3252 (-0.97%)

10:47
09/20/17
09/20
10:47
09/20/17
10:47
Conference/Events
Teleflex management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 01

    Dec

OFIX

Orthofix

$48.51

-0.49 (-1.00%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Conference/Events
Orthofix management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

PFE

Pfizer

$35.93

0.475 (1.34%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Options
Pfizer call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

10:45
09/20/17
09/20
10:45
09/20/17
10:45
General news
Euro$ interest rate futures are relatively buoyant »

Euro$ interest rate…

ZLAB

Zai Lab

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NKTR

Nektar

$21.75

-0.85 (-3.76%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Conference/Events
Nektar management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

MAT

Mattel

$15.05

0.18 (1.21%)

, HAS

Hasbro

$94.99

1.75 (1.88%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Hot Stocks
Toymakers in focus after Toys"R"Us files for bankruptcy, Amazon could benefit »

Shares of toymakers,…

MAT

Mattel

$15.05

0.18 (1.21%)

HAS

Hasbro

$94.99

1.75 (1.88%)

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

KKR

KKR

$19.24

0.15 (0.79%)

VNO

Vornado

$73.34

-0.03 (-0.04%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

WMT

Wal-Mart

$80.29

0.24 (0.30%)

JPM

JPMorgan

$94.12

0.18 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 10

    Oct

  • 12

    Oct

  • 22

    Oct

  • 23

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MODN

Model N

$13.35

-0.15 (-1.11%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Conference/Events
Model N management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

MMM

3M

$210.50

-3.06 (-1.43%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Hot Stocks
Analyst says sell 3M amid slowdown in autos, electronics »

JPMorgan downgraded 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ODP

Office Depot

$4.35

-0.07 (-1.58%)

, ADP

ADP

$107.48

0.93 (0.87%)

10:42
09/20/17
09/20
10:42
09/20/17
10:42
Hot Stocks
Office Depot says David Bleisch joins as Chief Legal Officer »

Office Depot (ODP)…

ODP

Office Depot

$4.35

-0.07 (-1.58%)

ADP

ADP

$107.48

0.93 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

10:40
09/20/17
09/20
10:40
09/20/17
10:40
Syndicate
Zai Lab indicated to open at $23, IPO priced at $18 »

Zai Lab (ZLAB) priced 8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

10:40
09/20/17
09/20
10:40
09/20/17
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

APC

Anadarko

$44.64

0.88 (2.01%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JCOM

j2 Global

$73.37

-1.52 (-2.03%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Conference/Events
j2 Global management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

PFE

Pfizer

$35.85

0.4 (1.13%)

, JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

10:34
09/20/17
09/20
10:34
09/20/17
10:34
Hot Stocks
Pfizer takes J&J to court as analysts shake up pharma ratings »

Morgan Stanley analyst…

PFE

Pfizer

$35.85

0.4 (1.13%)

JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

LLY

Eli Lilly

$82.24

0.505 (0.62%)

NVS

Novartis

$86.11

0.26 (0.30%)

ABBV

AbbVie

$86.90

0.53 (0.61%)

BMY

Bristol-Myers

$63.08

0.1532 (0.24%)

AGN

Allergan

$211.28

-3.725 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

  • 18

    Oct

  • 26

    Oct

  • 31

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

PFE

Pfizer

$35.91

0.455 (1.28%)

, PGR

Progressive

$47.57

-0.065 (-0.14%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

PFE

Pfizer

$35.91

0.455 (1.28%)

PGR

Progressive

$47.57

-0.065 (-0.14%)

AAL

American Airlines

$44.38

-0.93 (-2.05%)

LUV

Southwest

$53.77

0.23 (0.43%)

POST

Post Holdings

$86.68

0.32 (0.37%)

NDSN

Nordson

$114.62

0.12 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 18

    Oct

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.